研究单位：[1]Shanghai Jiaolian Drug Research and Development Co., Ltd[2]Shanghai Pharmaceuticals Holding Co., Ltd[3]Peking University First Hospital,Beijing,China[4]The First Bethune Hospital of Jilin University,Changchun,China[5]Xiangya Hospital Central South University,Changsha,China[6]Sichuan Provincial People's Hospital,Chengdu,China[7]Nanfang Hospital, Southern Medical University,Guangzhou,China[8]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China[9]Shandong Provincial Qianfoshan Hospital,Jinan,China[10]Shandong University Cheeloo College of Medicine,Jinan,China[11]First People's Hospital of Yunnan Province,Kunming,China[12]Jiangxi Provincial People's Hospital,Nanchang,China[13]The Second Affiliated Hospital of Nanchang University,Nanchang,China[14]Shandong University Cheeloo College of Medicine,Qingdao,China[15]Huashan Hospital, Fudan University,Shanghai,China[16]Shenzhen Hospital of University of Hong Kong,Shenzhen,China[17]Renmin Hospital of Wuhan University,Wuhan,China[18]Tongji Medical College of HUST,Wuhan,China[19]Tangdu Hospital,Xi'an,China[20]Affiliated Hospital of Zunyi Medical College,Zunyi,China
研究目的：
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
